Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | AHR | P35869 | 1/20 | 0.58 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 5/20 | 0.56 |
| ▸ | HTR6 | P50406 | 3/20 | 0.56 |
| ▸ | HTR2C | P28335 | 3/20 | 0.56 |
| ▸ | HTR1D | P28221 | 2/20 | 0.56 |
| ▸ | HTR1B | P28222 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | MPO | P05164 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30354035 | 1.00 | MEN1 (0.58) | MEN1KMT2ACYP3A4MAPTAHR | |
| Hydrochloric Acid SCHEMBL27797436 | 0.98 | PMP22 (0.57) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL27452680 | 0.89 | MEN1 (0.58) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL73842 | 0.85 | MEN1 (0.62) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL16366298 | 0.85 | MEN1 (0.53) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL11821215 | 0.85 | MEN1 (0.53) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL3944970 | 0.83 | MEN1 (0.51) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL11816093 | 0.83 | MEN1 (0.55) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL18647213 | 0.82 | MEN1 (0.50) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL11818699 | 0.82 | HTR2A (0.50) | MEN1KMT2ACYP3A4MAPTAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024804-A1 | PSILOCYBIN COMPOSITIONS | TURTLE BEAR HOLDINGS LLC (US) | 2023-01-26 | — | — | US | claimed |
| EP-0251938-B1 | STEREOSPECIFIC PROCESS FOR THE SYNTHESIS OF INDOLE DERIVATIVES | SANOFI (FR) | 1991-11-06 | — | — | EP | claimed |
| US-4977274-A | REACTING PROTECTED GLYCIDYLOXYINDOLE WITH AMINE, DEPROTECTING | SANOFI (FR) | 1990-12-11 | — | — | US | claimed |
| EP-0338352-A2 | Salicylic acid derivatives | MERCK PATENT GmbH (DE) | 1989-10-25 | — | — | EP | claimed |
| EP-0228356-B1 | HYDROXY-4-INDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | SANOFI S.A. (FR) | 1989-08-02 | — | — | EP | claimed |
| US-4806655-A | Process for the stereospecific synthesis of indole derivatives | SOCIETE ANONYME: SANOFI (FR) | 1989-02-21 | — | — | US | claimed |
| CN-118234491-A | Hallucinogen-fatty acid combinations | 明德赛特制药公司 | 2024-06-21 | — | — | CN | disclosed |
| US-11896587-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLP (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230218603-A1 | PSILOCYBIN COMPOSITIONS | TURTLE BEAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | disclosed |
| CN-112679495-B | Estrogen receptor modulators | 里科瑞尔姆IP控股有限责任公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-11452712-B2 | Methods and compositions involving (S)-bucindolol | ARCA BIOPHARMA INC. (US) | 2022-09-27 | — | — | US | disclosed |
| CN-113717170-A | Estrogen receptor modulators | 里科瑞尔姆IP控股有限责任公司 | 2021-11-30 | — | — | CN | disclosed |
| US-4522824-A | ADRENERGIC BLOCKING AGENTS | SANOFI (FR) | 1985-06-11 | — | — | US | disclosed |
| US-4517188-A | HYPOTENSIVE AGENTS, VASODILATORS, ADRENERGIC BETA BLOCKERS | MEAD JOHNSON & COMPANY (US) | 1985-05-14 | — | — | US | disclosed |
| US-4495352-A | HYPOTENSIVE AGENTS; VASODILATION; ADRENERGIC BLOCKING ACTION | MEAD JOHNSON & COMPANY (US) | 1985-01-22 | — | — | US | disclosed |
| EP-0130878-A1 | Hexahydroindolonaphthyridine derivatives, their preparation and therapeutic use | SYNTHELABO (FR) | 1985-01-09 | — | — | EP | disclosed |
| US-4314943-A | ANTIHYPERTENSIVE AGENTS; VASODILATORS | MEAD JOHNSON & COMPANY (US) | 1982-02-09 | — | — | US | disclosed |
| US-4234595-A | HYPOTENSIVE AGENTS; ADRENERGIC BLOCKING AGENTS; VASODILATION | MEAD JOHNSON & COMPANY (US) | 1980-11-18 | — | — | US | disclosed |
| US-3947584-A | Novel indolyl alkyl amines, method of producing same, and their use as anorectic agents | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11896587-B2 | Tryptamine compositions for enhancing neurite outgrowth | HTR1B, HTR6, BDNF | MEN1 1443/4885KMT2A 2403/4885CYP3A4 2427/4885 |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | MEN1 1772/4885KMT2A 2510/4885CYP3A4 3860/4885 |
| US-20230218603-A1 | PSILOCYBIN COMPOSITIONS | NES, PNMT, GAP43 | MEN1 525/4885KMT2A 3730/4885CYP3A4 3329/4885 |
| US-20230024804-A1 | PSILOCYBIN COMPOSITIONS | NES, PNMT, GAP43 | MEN1 525/4885KMT2A 3730/4885CYP3A4 3329/4885 |
| US-11452712-B2 | Methods and compositions involving (S)-bucindolol | ADRB3, ADRB2, ADRB1 | MEN1 3096/4885KMT2A 4746/4885CYP3A4 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.